Why the ResMed (ASX:RMD) share price is rising

The ResMed (ASX:RMD) share price is up around 5% despite the ASX having a fairly rough day. It announced its third quarter update.
asx-pnv-healthcare-shares-doctor-medical

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The ResMed (ASX: RMD

online pharmacy buy robaxin no prescription

) share price is up around 5% despite the ASX having a fairly rough day. It announced its third quarter update.

What is ResMed?

Resmed is a United States based business that develops and manufactures medical devices to help people with sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed, which is short for Respiratory Medicine, was founded in 1989 by Dr Peter Farrell and now helps customers & patients in over 120 countries.

What did ResMed reveal?

buy https://goodsamgwinnett.org/wp-content/uploads/2017/05/17.html online https://goodsamgwinnett.org/wp-content/uploads/2017/05/17.html no prescription pharmacy

The healthcare business announced that revenue rose by 16% to $769.5 million. It was a rise of 17% on a constant currency basis.

ResMed said that its non-GAAP (generally accepted accounting practices) gross margin increased by 70 basis points (0.70%) to 60%.

Its net operating profit increased by 39%, whereas the non-GAAP profit growth was slightly slower at 31%.

On the one hand the company’s life support ventilators, non-invasive ventilators and ventilation mask systems have seen enormous demand. This is what has largely driven the result. The sleep apnea side of the business saw less exciting growth, but it still did quite well.

The ‘software as a service’ division also did well with 12% revenue growth thanks to a good performance by Brightree and MatrixCare.

ResMed CEO Mick Farrell said: “Looking ahead, we are confident in our ability to navigate through the challenging clinical and economic environment to deliver for all our stakeholders. Our culture, operational resilience, strong balance sheet, business continuity plans and growth prospects have positioned us well.”

Thinking about buying ResMed? It’s likely to see good demand for the rest of the year. But it’s a question of whether you aim for a much cheaper share that’s been hit hard, or a (comparatively) more expensive business that keeps growing.

These technology shares could be better ideas to buy:

[ls_content_block id=”18457″ para=”paragraphs”]

Disclosure: at the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.

Live webinar (with Q&A)

Earnings Season Whiplash
Why prices jump and crash, and how to think clearly when results hit

  • Presented by Owen Rask & Leigh Gant
  • Monday, 16 February   | 7pm AEDT 

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Build a better financial future, one Sunday at a time

Join over 50,000 savvy Australians receiving Rask’s free weekly email packed with investing insights, personal finance education, and the global stories that can shape your money decisions.


Because breaking down the barriers to finance is how more people learn to invest, build wealth and live life on their terms.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.